# Lantheus and GE Healthcare sign license agreement for flurpiridaz F 18

Lantheus Holdings and GE Healthcare signed a definitive license agreement for the continued Phase III development and worldwide commercialization of flurpiridaz F 18, an investigational PET MPI agent. GE Healthcare will lead and fund development and have exclusive worldwide commercialization rights.

- Type: Contract
- Announced: 2017-04-25
- Value: $5.00M
- Status: completed
- Products: flurpiridaz F 18, TechneLite, Gallium-67, Xenon-133
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Lantheus Holdings](https://endata.com/companies/23794.md)
- [GE Healthcare](https://endata.com/companies/4246.md) (customer)

## Sources

- [businesswire.com](https://www.businesswire.com/news/home/20170425005873/en/Lantheus-GE-Healthcare-Announce-Signing-Definitive-License/?feedref=JjAwJuNHiystnCoBq_hl-ZuHAZxVRaQvQ0qaekuSK9f3_P53wLuJwyFVA4-mOrLx7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCN1Simk7pbS0xXPOT069Puw==), 2017-04-25: "With our definitive agreement for flurpiridaz F 18 in place, we look forward to collaborating with GE Healthcare to complete the development and commercialization efforts to bring this novel PET cardiac imaging agent to market."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.